insights_auto
Why is ALNY up 3.63%?
Dive Deeperchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$232.68
arrow_upward
+3.63%(+8.15) 1D
$232.68
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$224.74
High
$232.94
Low
$222.70
Mkt. cap
31.13B
Avg. vol.
1.50M
Volume
959.45K
P/E ratio
39.60
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
Open
$224.74
High
$232.94
Low
$222.70
Mkt. cap
31.13B
Avg. vol.
1.50M
Volume
959.45K
P/E ratio
39.60
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
Simply Wall Street
·
9 hours ago
Alnylam Pharmaceuticals (ALNY) Could Be 37% Undervalued After TTR Sales Probe
Yahoo Finance
·
10 hours ago
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.